AUNA

AI MemoPost-earnings T+1

Auna

As of 2026-08-19/Post-earnings T+1/Confidence low

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-19 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

low

Horizon

—

Key catalyst

2Q26 financial disclosure and management follow-up • 2026-08-19

Base target: $6 / p=50% prob

Biggest risk

The packet does not provide verifiable 2Q26 reported revenue, EPS, EBITDA, cash flow, guidance status, transcript commentary, analyst estimate revisions, or target changes. The preliminary KPI release explicitly warns that final metrics may differ, leaving execution and margin risk unresolved.

Invalidation

Break below $4 or thesis failure.

What would change my mind?

Preliminary 2Q26 activity was constructive across several operating indicators, especially Peru utilization, oncology memberships, Mexico surgeries, and Colombia protected lives. If the unavailable full-quarter financials confirm volume conversion and preserve FY26 targets, the low market capitalization and packet target median of $7.2906 leave room for rerating.

Research note

Recommendation

—

Confidence

low

As of

2026-08-19

Base target

p=50%

Bull target

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Unresolved earnings-validation risk
Volume, utilization, and membership momentum
Preliminary 2Q26 activity was constructive across several operating indicators, especially Peru utilization, oncology memberships, Mexico surgeries, and Colombia protected lives.

BearKey bullets

A director open-market purchase is supportive sentiment context only and is not evidence of operating performance.
[#SEC-FORM4-2026-06-01]
Low coverage, small market capitalization, and loose peer comparability increase volatility and information risk.

WatchKey bullets

2Q26 financial disclosure and management follow-up

Summary

High-level snapshot

Recommendation

Model confidence

low

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $6 (p=50%)

Target spread vs base: +24% / -25%

Scenario probabilities

Bull Target: $7 (p=20%)Base Target: $6 (p=50%)Bear Target: $4 (p=30%)

Commentary

Headline activity is concentrated around the scheduled 2Q26 reporting cycle, but social, options, short-interest, employee, and trusted post-print analyst data are unavailable. The packet's anchor is $5.42 on August 18; no checked source reliably attributes a subsequent price move to results. Evidence supports monitoring rather than a high-conviction directional call.

As of 2026-08-19 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Unresolved earnings-validation risk
Volume, utilization, and membership momentum

Scenarios

Bull Target (Scenario probability)

$7 / p=20% prob

Base Target (Scenario probability)

$6 / p=50% prob

Bear Target (Scenario probability)

$4 / p=30% prob

Analysis 2026-08-19 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-19
2Q26 financial disclosure and management follow-up
The packet records Auna's 2Q26 results release on August 18 and call on August 19. The checked investor-relations material confirms the quarter's preliminary operating metrics but did not provide a verifiable detailed financial surprise, guidance change, or transcript. This remains the key near-term proof point. [#IR-2026-07-20]
Prob 70.00% • Move 8.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Unresolved earnings-validation risk
2026-08-31
The primary material checked does not yet verify 2Q26 revenue, EPS, margins, cash flow, management guidance, analyst revisions, or a results-linked market reaction. Auna's own preliminary-results warning means any operating improvement could fail to translate into reported earnings. [#IR-2026-07-15]
Prob 55% • Move -9% • Priced-in 35%

Long-term Catalysts

Months to a year

Volume, utilization, and membership momentum
2026-09-30
Preliminary 2Q26 metrics showed Mexico surgeries of 5,193, Peru capacity utilization of 80.2%, OncoSalud memberships of 1,472,019, and Colombia protected lives of 3,143,694. These trends are directionally supportive, but Auna cautioned that the data were preliminary and may change, so financial conversion into revenue, EBITDA, and cash flow remains unproven. [#IR-2026-07-15]
Prob 55% • Move 12% • Priced-in 45%

Risks

A director open-market purchase is supportive sentiment context only and is not evidence of operating performance. [#SEC-FORM4-2026-06-01]
Low coverage, small market capitalization, and loose peer comparability increase volatility and information risk.
Mexico recovery and Peru margin normalization remain execution-sensitive.
No verified 2Q26 earnings surprise, guidance update, or analyst revision is available in the checked sources.
Preliminary operating metrics may change and do not establish revenue, EBITDA, margin, or cash-flow conversion. [#IR-2026-07-15]

Peers

Symbol	Summary
BSX	Large-scale cardiovascular and medtech benchmark; useful for sector risk appetite and quality comparisons, but not a direct read-through to Auna's Latin American integrated healthcare-services and plan model.
ABT	Diversified healthcare and device reference with much greater scale and broader product exposure; limited operating comparability, mainly useful as a broad medtech valuation anchor.
CYH	Closer healthcare-services risk reference by size, but its U.S. hospital footprint, leverage, and business mix differ materially; peer value is primarily small-cap healthcare risk framing.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-19

Loading AI feed…

Symbol

Summary

BSX

Large-scale cardiovascular and medtech benchmark; useful for sector risk appetite and quality comparisons, but not a direct read-through to Auna's Latin American integrated healthcare-services and plan model.

ABT

Diversified healthcare and device reference with much greater scale and broader product exposure; limited operating comparability, mainly useful as a broad medtech valuation anchor.

CYH

Closer healthcare-services risk reference by size, but its U.S. hospital footprint, leverage, and business mix differ materially; peer value is primarily small-cap healthcare risk framing.